AI Drugs Could Be Available By 2030
Source: chemindigest.com
According to Alex Zhavoronkov, CEO of Insilico Medicine, the first drugs entirely developed through AI could be available by the end of this decade. Zhavoronkov anticipates this could happen in the next five to six years.
This outlook is part of a larger trend in the pharmaceutical industry, where AI is becoming more important. While no AI-designed drug has been approved, progress is being made. The pharmaceutical sector has noted AI’s potential to lower drug development time and costs. Companies are progressing to late-stage trials. For example, Takeda Pharmaceutical is in the final phase of clinical testing for a psoriasis treatment selected using AI; trial results are expected later this year.
Insilico Medicine's Approach
Zhavoronkov says Insilico’s full-spectrum use of AI sets it apart. Insilico uses the technology throughout the drug development lifecycle—from identifying targets to optimizing drugs—to deliver candidates ready for human trials. Insilico has locations in the U.S., China, the Middle East, and Canada.
Recent Developments
The company recently refiled for a public listing on the Hong Kong stock exchange after a private funding round that valued it at over US$1 billion. Insilico Medicine is leading a shift in drug discovery as the AI race in biotech advances. AI-designed therapies could soon be available, changing R&D and patient care, according to freemalaysiatoday.com.